Best Pancreatic Cancer Hospital in Hyderabad - 11 Centres, NCCN Protocols, NABH-Accredited Partners

Pancreatic cancer treatment combines surgery, chemotherapy, sometimes radiation, and supportive care for the digestive complications that come with the disease and its treatment. The team needs a surgical oncologist or hepatobiliary surgeon trained in Whipple surgery, a medical oncologist experienced with the standard chemotherapy combinations used for pancreatic cancer (FOLFIRINOX and gemcitabine + nab-paclitaxel), a radiation oncologist familiar with high-precision focused radiation, a gastroenterologist who can perform endoscopic ultrasound with biopsy, an interventional gastroenterologist for biliary stenting when jaundice is present, a pathologist with experience in pancreatic biopsies, and a nutritionist for long-term digestive care after surgery.

Walk away if the hospital cannot name who will manage your tissue biopsy and who will manage your post-Whipple nutrition.

Pancreatic cancer tumour boards do something distinctive: they classify each case as resectable (the tumour can be removed with clear margins), borderline resectable (the tumour touches major blood vessels but is potentially removable with vascular reconstruction), locally advanced (the tumour encases blood vessels and cannot be removed), or metastatic (cancer has spread). This classification decides whether you go to surgery first, get chemotherapy first to shrink the tumour before considering surgery (an approach increasingly standard for borderline cases), or move directly to chemotherapy without surgery.

Walk away if surgery is recommended in the first consultation without a documented tumour-board discussion of resectability.

If you take only one thing from this page, take this: in pancreatic cancer, hospital and surgeon Whipple volume is the most evidence-based outcome predictor in all of cancer surgery. High-volume centres demonstrate post-operative mortality of 1-3% and dramatically lower complication rates compared to 8-15% mortality at low-volume centres. Ask: "How many Whipple procedures did your team perform last year? What is your 30-day and 90-day mortality? What is your bile leak and post-operative pancreatic fistula rate?" Specific numbers indicate transparency.

Walk away if volume is described as "many" - no specific number offered. This is the question that matters more than any other.

Pancreatic cancer needs a specific kind of imaging called a pancreatic-protocol CT scan, which uses multiple contrast phases to map the tumour's exact relationship to the major blood vessels behind the pancreas. MRI with a study of the pancreatic ducts (called MRCP) adds detail about ductal anatomy and possible liver spread. Tissue diagnosis is established through endoscopic ultrasound with biopsy, where a slim ultrasound probe is passed through the mouth into the stomach to sample the tumour with a fine needle - far safer than a needle through the skin. A baseline blood tumour marker (CA 19-9) helps track response. For families with multiple cancers, BRCA1, BRCA2, and PALB2 gene testing can identify patients who will benefit from olaparib.

Walk away if the hospital recommends surgery without an endoscopic ultrasound or a pancreatic-protocol CT.

Pancreatic cancer chemotherapy is intensive - modern combination regimens like FOLFIRINOX (a four-drug combination used in fit patients) and gemcitabine + nab-paclitaxel (the standard combination for patients who cannot tolerate FOLFIRINOX) require infusions every two or three weeks for many months. These regimens are used both before surgery (called neoadjuvant chemotherapy, increasingly standard for borderline-resectable tumours) and after surgery as preventive treatment to reduce the chance of recurrence. Patients with inherited BRCA mutations may continue on olaparib, an oral targeted pill, as maintenance treatment.

Walk away if all chemotherapy is administered at one campus only - that's a logistical burden over six to twelve months of treatment.

Pancreatic cancer care routinely calls on procedures that need specialised infrastructure - the Whipple procedure itself, robotic-assisted Whipple surgery (which some surgeons prefer for selected cases), biliary stenting through endoscopy to relieve obstructive jaundice before chemotherapy, and high-precision focused radiation (SBRT) for locally advanced tumours that cannot be removed surgically. NABH-accredited partners signal audited surgical and procedural safety.

Walk away if the hospital says "we'll refer you out if needed" but cannot name the surgical centre, endoscopy unit, or accreditation status.

Pancreatic cancer treatment is among the most expensive cancer pathways - Whipple surgery alone runs into several lakh, chemotherapy continues for many months, and supportive care for digestive complications adds to the bill. A hospital that isn't empanelled for your insurance or ArogyaSri at the specific centre where your procedure happens can derail planning at the worst moment.

Walk away if cost estimates change after admission - a serious hospital writes them down beforehand.

Patients who have had a Whipple procedure live with permanent changes to their digestion. Most need pancreatic enzyme replacement to digest food, many develop diabetes if the surgery affected the insulin-producing parts of the pancreas, and weight loss in the months after surgery is common and needs active management. You will see your team frequently - for follow-up scans, blood tumour marker tracking, nutritional support, and diabetes management. A hospital an hour away makes every visit a half-day; a network of centres close to home - same panel, same protocols, shared records - makes continuity sustainable.

Walk away if you're told you must travel to one campus for every nutritional review and follow-up scan.

Hospital infrastructure for pancreatic cancer is tiered at CION. Detailed scans, endoscopic ultrasound coordination, day-care chemotherapy, nutritional follow-up, and blood-marker surveillance happen at the centre nearest your home. Whipple surgery, distal pancreatectomy, robotic-assisted Whipple, biliary stenting, and high-precision focused radiation run through NABH-accredited partner hospitals with verified annual surgical volume. The same oncology team that consults at one centre stays with you across the network.

CT, MRI, and PET-CT imaging - including the pancreatic-protocol multi-phase contrast CT required for accurate staging and resectability assessment - are available across six CION centres in Hyderabad. Endoscopic ultrasound for tissue diagnosis is coordinated through partner gastroenterology services. Imaging is reviewed by treating oncologists alongside the CION pathology team, with turnaround designed to keep treatment on schedule.

Around 10% of pancreatic cancers carry an inherited mutation in genes such as BRCA1, BRCA2, PALB2, or genes linked to Lynch syndrome. CION arranges genetic testing through integrated lab pathways where family history or clinical features suggest an inherited cause. Patients with BRCA-positive metastatic pancreatic cancer may qualify for olaparib, an oral targeted pill called a PARP inhibitor that improves outcomes specifically in this subgroup.

All 11 CION centres in Hyderabad have day-care infusion bays. FOLFIRINOX, modified FOLFIRINOX, gemcitabine + nab-paclitaxel, gemcitabine + capecitabine, and olaparib regimens for pancreatic cancer are administered close to home - used both before surgery as neoadjuvant chemotherapy for borderline tumours, after surgery as preventive treatment, and in advanced disease. Oncology-trained nursing, infusion-reaction protocols, and on-site oncologist supervision are standard at every centre.

Where a pancreatic cancer case requires Whipple surgery, distal pancreatectomy, robotic-assisted Whipple for selected cases, biliary stenting through endoscopy to relieve jaundice before chemotherapy, or high-precision focused radiation for locally advanced unresectable tumours, CION coordinates the procedure through NABH-accredited partner hospitals with verified high annual surgical volume. NABH accreditation ensures audited compliance with patient-safety, infection-control, and clinical-governance protocols. You get specialist procedural capability - at a hospital that actually does the volume - without leaving the CION pathway.

Patients who have had a Whipple procedure live with permanent changes to digestion. Pancreatic enzyme replacement to digest food, screening and management for diabetes that may develop after surgery, weight monitoring and active nutritional support, biliary stent management when jaundice has been relieved before chemotherapy, pain management for the abdominal and back pain that pancreatic cancer can cause, and psychological support are all coordinated within the CION network. These are not afterthoughts - they decide whether your recovery is uncomplicated or whether a single complication turns into a re-admission.

Every pancreatic cancer case at CION is reviewed by the multidisciplinary tumour board before the treatment plan is finalised. The board debates the resectability classification, the timing of surgery (upfront vs after chemotherapy for borderline tumours), the right chemotherapy combination, gene-testing decisions, preventive chemotherapy after surgery, and high-precision radiation for locally advanced cases. The board produces a written summary that becomes part of your records - and yours to keep. You can take it to any second opinion, anywhere.